2012年1月10日

由安吉拉·索爾oncom製成藥品,臨床分期公司發展目標癌症幹細胞療法,促進了Jakob杜邦、前副總統,臨床研究高級副總裁和首席醫療官。民營、oncom製成的投資者包括美國合資企業夥伴Latterell Venture Partners,垂直集團morgenthal的企業,Phase4企業,德爾福企業,亞當斯街夥伴,新創企業,海灣合作夥伴和葛蘭素史克。新聞稿oncom製成藥品公司,私營,臨床分期公司發展新的療法,針對癌症幹細胞,今天宣布晉升Jakob杜邦,醫學博士臨床研究,前副總裁,高級副總裁兼首席醫療官。杜邦公司在10月份加入oncom製成基因泰克博士,羅氏集團的一員,他是全球醫療主任阿瓦斯丁®(貝伐單抗)。博士現在杜邦頭oncom製成的全球開發團隊,負責推進多個小說抗癌幹細胞療法在臨床發展的所有階段。加入oncom製成之前,杜邦博士負責基因泰克的全球醫療策略,阿瓦斯丁和後期醫療項目,擔任阿瓦斯丁發言人全球投資界。杜邦博士收到了他在紐約康奈爾大學醫學院的醫學學位,繼續他的訓練內科密歇根大學和紐約長老會醫院。他完成了他的醫學腫瘤學獎學金紀念斯隆-凱特林癌症中心(MSKCC)。杜邦博士有一個廣泛的免疫學實驗室研究背景,分子生物學,基因治療和轉化醫學。他教師的一員MSKCC五年了,在加入Genentech /羅氏,監督第一階段固體腫瘤,婦科腫瘤診所。 He was also head of a translational and immunology laboratory at MSKCC. Dr. Dupont has received numerous grants and awards, authored over 40 peer-reviewed scientific articles and holds several patents. He continues to care for gynecologic oncology patients and teach as an Adjunct Clinical Assistant Professor at Stanford University Medical Center. About Cancer Stem Cells Cancer stem cells, a small, resilient subset of cells found in tumors, have the capacity to self-renew and differentiate, leading to tumor initiation and driving tumor growth, recurrence and metastasis. Also referred to as “tumor-initiating cells,” these cells were first discovered by OncoMed’s scientific founders in breast cancer and have subsequently been identified in many other types of solid tumor cancers, including cancer of head and neck, lung, prostate, pancreas and glioblastoma. Cancer stem cells appear to be preferentially resistant to both standard chemotherapy and radiotherapy. OncoMed’s strategy is to improve cancer treatment by specifically targeting the key biologic pathways that are thought to be critical to the activity and survival of cancer stem cells. OncoMed’s antibody therapeutics target cancer stem cell proteins and have the potential to be developed against a range of tumor types. About OncoMed Pharmaceuticals OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed has advanced three anti-cancer stem cell monoclonal antibodies into the clinic, OMP-21M18, OMP-59R5 and OMP-18R5, which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMed’s pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways. OncoMed has formed strategic alliances with Bayer HealthCare Pharmaceuticals and GlaxoSmithKline. Privately-held, OncoMed’s investors include: US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline. © 2015 Buyouts Insider / Argosy Group LLC